Dr. Choi on the long-term efficacy of first-line ibrutinib in CLL


Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a first-line treatment in chronic lymphocytic leukemia.

Michael Choi, MD, medical hematologist / oncologist, associate professor of medicine, Moores Cancer Center, University of California at San Diego Health, discusses the long-term effectiveness of ibrutinib (Imbruvica) given as a first-line treatment in the chronic lymphocytic leukemia (CLL).

BTK inhibitors have an established role in the treatment of patients with CLL, explains Choi. Long-term follow-up data from the phase 3 RESONATE-2 trial (NCT01722487) demonstrated that up to 7 years of follow-up, ibrutinib monotherapy conferred sustained progression-free survival and an overall survival benefit over with chlorambucil in patients 65 years of age or older with previously untreated CLL. These data are reassuring for patients and their families because it suggests that most patients with CLL who start treatment with ibrutinib will achieve lasting remissions, explains Choi.

Additionally, responses with ibrutinib were observed regardless of high-risk genomic characteristics, such as 11q deletions, TP53 mutations and not mutated IGHV status.

Regarding safety, the rates of atrial fibrillation, arterial hypertension and bleeding events remained low with ibrutinib. However, it is important to be vigilant about toxicities so that they can be alleviated early in patients receiving ibrutinib, Choi concludes.

Source link


Comments are closed.